Haleon (HLN) to Announce Quarterly Earnings on Thursday

Haleon (NYSE:HLN) is anticipated to release its H2 2025 results before the market opens on Thursday, February 26th. Analysts expect Haleon to post earnings of $0.2512 per share and revenue of $2.7637 billion for the quarter. Investors are encouraged to explore the company’s upcoming H2 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 2:00 AM ET.

Haleon Stock Down 0.0%

HLN stock opened at $11.08 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. The firm has a market capitalization of $49.33 billion, a P/E ratio of 28.41 and a beta of 0.19. Haleon has a 52-week low of $8.71 and a 52-week high of $11.42. The company’s 50 day simple moving average is $10.40 and its 200-day simple moving average is $9.79.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Parkside Financial Bank & Trust raised its stake in shares of Haleon by 101.3% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after purchasing an additional 1,433 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after buying an additional 1,203 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Haleon by 428.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock valued at $57,000 after acquiring an additional 5,124 shares during the last quarter. Cary Street Partners Financial LLC lifted its stake in Haleon by 20.1% in the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock valued at $69,000 after acquiring an additional 1,113 shares during the last quarter. Finally, McMillan Office Inc. bought a new stake in Haleon in the fourth quarter worth approximately $92,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft lowered Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.